CTOs on the Move

Inteprod

www.inteprod.com

 
Inteprod LLC is a Norristown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.inteprod.com
  • 970 Rittenhouse Rd
    Norristown, PA USA 19403
  • Phone: 610.650.9002

Executives

Name Title Contact Details

Similar Companies

Hardy Diagnostics

Hardy Diagnostics is a Santa Maria, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Iowa Hearing Aid Center

Iowa Hearing Aid Center is a Cedar Rapids, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greater Roslindale Medical and Dental Center

Greater Roslindale Medical and Dental Center is a Roslindale, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Solutions

At Medical Solutions, we connect care for our clients, traveling nurses and clinicians, and our internal employees. We help our clients find the perfect clinical, community and cultural fit with their traveling nurses and staff. Our travelers receive the best service in the industry from recruiters invested in their professional and personal success. Our employees work for a mission they believe in, with pride of representing one of the most respected brands in the healthcare staffing industry. We serve acute-care hospitals, post-acute care facilities, community health centers and other healthcare settings nationwide. We offer travel staffing as well as a managed service provider (MSP) program, strike solutions for hospitals, and a rapid response program for hospitals with urgent, flexible staffing needs. Our dedicated Client Managers ensure your facility`s unique needs, challenges and goals are met in a cost-effective manner.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.